Comparative Pharmacology
Head-to-head clinical analysis: AMARYL versus DIABINESE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMARYL versus DIABINESE.
AMARYL vs DIABINESE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonylurea that stimulates insulin secretion from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on ATP-sensitive potassium channels, causing channel closure and calcium influx.
Sulfonylurea that stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels, leading to cell depolarization and calcium influx. Also may increase peripheral insulin sensitivity.
Initial dose 1-2 mg orally once daily, titrated to target glucose. Maximum dose 8 mg daily.
Initial: 250 mg orally once daily, increase by 125-250 mg every 1-2 weeks as needed. Maintenance: 100-500 mg once daily. Maximum: 750 mg daily.
None Documented
None Documented
Terminal elimination half-life is 5-7 hours; clinically, dosing is once daily due to sustained glucose-lowering effect beyond half-life.
Terminal elimination half-life 25–36 hours; in renal impairment, half-life prolonged significantly.
Approximately 60% excreted renally as metabolites (mainly M1 and M2) and 40% in feces; <1% excreted unchanged.
Primarily renal (up to 80% unchanged); minor fecal (biliary) excretion (<10%).
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic